指南与共识乳腺外科

美国乳腺外科医师学会指南对单侧乳腺癌对侧预防性乳房切除术率的影响评估

Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer.
指南 / 共识 · Surgery · 2023-10-19

2016年7月美国乳腺外科医师学会发布指南不鼓励平均风险单侧乳腺癌女性行对侧预防性乳房切除术,本研究将其与结构化患者咨询结合,评估该举措对3208例患者对侧预防性乳房切除术率的影响。结果显示对侧预防性乳房切除术率在2017至2019年(55%)较2015至2016年(62%)显著下降(P = .01),但2020至2022年回升至61%;基因检测率从指南前27%升至2020至2022年74%。结论认为结构化患者咨询有效降低对侧预防性乳房切除术率,但需进一步教育。

要点

  • 对侧预防性乳房切除术率2017至2019年(55%)较2015至2016年(62%)显著下降(P = .01),2020至2022年回升至61%。
  • 基因检测率从指南前27%升至2020至2022年74%,致病性变异比例从4%升至11%(P < .001)。
  • 在检测无致病性变异和未检测患者中,对侧预防性乳房切除术率分别从78%降至67%和从48%降至38%(P < .001)。

核心结论

  • 实施特定患者咨询有效降低了对侧预防性乳房切除术率,但作者认为需进一步教育努力以影响对侧预防性乳房切除术率,尤其基因检测阴性情况下。

研究设计与样本

  • 评估2011年1月至2022年11月在本机构接受乳房切除术的单侧乳腺癌女性患者,分析对侧预防性乳房切除术相关变量及时间趋势,使用Wilcoxon秩和检验或χ2分析。

主要发现

  • 3208例患者中位年龄54岁,1366例(43%)接受单侧乳房切除术,1842例(57%)同时接受对侧预防性乳房切除术。
  • 对侧预防性乳房切除术率2017至2019年(55%)较2015至2016年(62%)显著下降(P = .01),但2020至2022年回升至61%。
  • 总体即刻乳房重建率为70%,对侧预防性乳房切除术组为81%,非对侧预防性乳房切除术组为56%(P < .001)。
  • 基因检测率从指南前27%升至2020至2022年74%,致病性变异比例从指南前4%升至2020至2022年11%(P < .001),其中91%接受了对侧预防性乳房切除术。
  • 在检测无致病性变异患者中,对侧预防性乳房切除术率从指南前78%降至指南后67%;在未检测患者中从48%降至38%(P < .001)。

关键数值与推荐

  • 美国乳腺外科医师学会2016年7月发布指南不鼓励平均风险单侧乳腺癌女性行对侧预防性乳房切除术。

临床怎么用

  • 本研究中心将指南纳入实践并结合结构化患者咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In July 2016, the American Society of Breast Surgeons published guidelines discouraging contralateral prophylactic mastectomy for average-risk women with unilateral breast cancer. We incorporated these into practice with structured patient counseling and aimed to assess the effect of this initiative on contralateral prophylactic mastectomy rates. METHODS: We evaluated female patients with unilateral breast cancer undergoing mastectomy at our institution from January 2011 to November 2022. Variables associated with contralateral prophylactic mastectomy and trends over time were analyzed using the Wilcoxon rank sum test or χ2 analysis as appropriate. RESULTS: Among 3,208 patients, (median age 54 years) 1,366 (43%) had a unilateral mastectomy, and 1,842 (57%) also had a concomitant contralateral prophylactic mastectomy. Across all patients, contralateral prophylactic mastectomy rates significantly decreased post-implementation from 2017 to 2019 (55%) vs 2015 to 2016 (62%) (P = .01) but increased from 2020 to 2022 (61%). Immediate breast reconstruction rate was 70% overall (81% with contralateral prophylactic mastectomy and 56% without contralateral prophylactic mastectomy, P < .001). Younger age, White race, mutation status, and earlier stage were also associated with contralateral prophylactic mastectomy. Genetic testing increased from 27% pre-guideline to 74% 2020 to 2022, as did the proportion of patients with a pathogenic variant (4% pre-guideline vs 11% from 2020-2022, P < .001), of whom 91% had a contralateral prophylactic mastectomy. Among tested patients without a pathogenic variant and patients not tested, contralateral prophylactic mastectomy rates declined from 78% to 67% and 48% to 38% pre -and post-guidelines, respectively, P < .001. CONCLUSION: Implementation of specific patient counseling was effective in decreasing contralateral prophylactic mastectomy rates. While recognizing that patient choice plays a significant role in the decision for contralateral prophylactic mastectomy, further educational efforts are warranted to affect contralateral prophylactic mastectomy rates, particularly in the setting of negative genetic testing.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Steadman JA, Hoskin TL, Klassen C, et al. Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer. Surgery. 2023. PMID: 37863697. doi:10.1016/j.surg.2023.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。